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ABSTRACT
Objective: This study assesses the epidemiological pattern of lung cancer cell-types in Ireland, with identification of any 
underlying gender variations.
Methods: Lung cancer incidence data, including the major cell-types: squamous-cell-carcinoma (SCC), adenocarcinoma (AC), 
small-cell-lung-carcinoma (SCLC) and large-cell-carcinoma (LCC) were obtained from the national cancer registry (1994-2000), 
together with individual characteristics, such as age, gender, smoking status, and the year of diagnosis. Age-standardised incidence 
rates (ASIR), male-to-female (M: F) rate ratios (RR) of ASIR for SCC and AC, as well as RR of AC: SCC according to smoking 
status for both sexes, were estimated. Estimated-annual-percent-changes for each of the cell-types were calculated. 
Results: AC incidence in females is rising annually (8.5%, p=0.008) from 1994 to 2000, while SCC is declining (-5.4%, p=0.01) 
in males. M: F ratios of ASIR are consistently greater than ‘one’, but converging recently. RR of AC: SCC is also approaching 
‘unity’ across both sexes, irrespective of the smoking status
Conclusions: An apparent increase in lung AC incidence in females was observed in Ireland that might indicate some local 
environmental risk factors, in addition to changing smoking habits. The study findings do not support the hypothesis that females 
in general are at higher risk for lung cancer development, but tobacco and histologic-specific susceptibility cannot be ruled 
out.
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INTRODUCTION
Lung cancer occurs in multiple histological cell-types. The 
four major cell-types include squamous cell carcinoma (SCC), 
adenocarcinoma (AC), large cell carcinoma (LCC), and small 
cell carcinoma (SCLC). Together, these four major cell-types 
account for >90% of lung cancer cases in the United States 
(US)1. Despite extensive research, the mechanisms leading 
to  these  different  types  of  lung  cancer  remain  uncertain. 
Over  recent  decades  there  have  been  both  geographical 
and  temporal  changes  in  the  distribution  of  lung  cancer 
cell-types2-4. Knowledge of these modifications may help to 
recognize any underlying new aetiological and pathological 
mechanisms of lung cancer. 
Lung  adenocarcinoma  has  become  the  leading  cell-type 
in  North America2,  Europe3  and Asia4.This  increase  may 
partly  be  artefactual  and  involve  several  biases,  or  may 
be a real change5. Geographical and temporal trends also 
differ in males and females. A recent birth-cohort study in 
the US concluded that males and females may be ‘equally’ 
susceptible to developing lung cancer from a given amount of 
cigarette smoking, rather than supporting the hypothesis that 
females are more susceptible to developing lung cancer6. This 
was reinforced in a recent prospective study7. Nonetheless, the 
gender susceptibility to developing lung cancer is debatable, 
and is still speculated to be associated with gender differences 
in their background risk profiles8. 
To date, no such temporal variations in lung cancer incidence 
by major cell-types have been identified in the Republic of 
Ireland. Therefore, the overall aim of this study is to assess the 
epidemiological pattern of lung cancer cell-types in Ireland, 
with identification of any underlying gender and/or temporal 
variations.
METHODS
Source of lung cancer incidence data
The Irish National Cancer Registry Board based in Cork has 
been registering lung cancer incident cases from January 1st, 
19949. More than 90% of cancer cases are histopathologically 
verified, and the Registry has a centralised system of uniform 
data collection and quality assessment9. However, for lung 
cancer cases only 75% could be verified histo-pathologically9. 
At the time of this study, all lung cancer incident cases (on 
an  individual  basis)  registered  from  1994  to  2000  were © The Ulster Medical Society, 2008.
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obtained from the Registry. Specific individual covariates, 
such as age, gender, year of diagnosis, and smoking status 
(smokers, non-smoker or former smokers) were also collected 
for further analyses. Based on the morphology codes of the 
WHO International Histological Classification of Tumors10, 
invasive carcinomas of lung [ICD Codes: 9 (162) and 10 
(C34)] were categorized into four major cell-types. They are: 
SCC (ICD-O: 8051-52, 8070-76), SCLC (ICD-O: 8041-45), 
LCC (ICD-O: 8011-12, 8020-21, 8030-33), and AC (ICD-O: 
8050, 8140-246, 8260-571).
Estimation of age-standardised incidence rates (ASIR)
Incidence rates for total lung cancer cases in both sexes, 
together  with  the  major  cell-types,  were  age-standardised 
to the European Standard Population for better comparison. 
The estimated-annual-percent-changes (EAPC) in rates for 
each cell-type were calculated, using generalised log-linear 
regression model. The annual rates are adjusted for the gender 
and  age-specific  annual  smoking  prevalence  of  the  Irish 
population for the year 1994, as the baseline year. The annual 
gender and age-specific smoking prevalence for the year 1994 
was obtained from the publication of Lee and colleagues11.
Estimation of age-standardised incidence rate ratios (RR)
Annual male-to-female RR (with 95% confidence intervals: 
CI) from 1994 to 2000 was estimated for SCC, AC, and for 
total  lung  cancer  cases.  The  male-to-female  ratios  (with 
95% CI) were calculated using a spreadsheet (quick-calc) 
developed  by  Rothman12.  Ratios  more  than  one  would 
generally indicate that males have higher lung cancer rates, 
thereby the less likelihood of supporting the hypothesis that 
females  are  more  susceptible  to  developing  lung  cancer. 
Likewise, annual rate ratios of AC: SCC for both sexes was 
calculated according to their smoking status.
RESULTS
In total, 10,514 lung cancer incident cases (6,823 in males, 
3,691 in females) were registered in the Republic of Ireland 
from 1994 to 2000. Of these, SCC was the most frequent 
cell-type in both males (34%) and females (22%), while AC 
was relatively high among female populations across all the 
periods studied (18% vs. 14% in males). The frequency of 
SCLC was also high in females (17% vs. 12% in males); 
LCC was the least frequent cell-type across both sexes (3%). 
In all our analyses where appropriate, we have combined 
both former and current smokers as ever-smokers for better 
estimates.
The overall ASIR across all the periods studied was higher 
in males (on an average 500 cases / 10,000 smokers) than in 
females (on an average 300 cases / 10,000 smokers). Total 
lung  cancer  incidence  is  significantly  increasing  annually 
(2%,  p=0.001)  in  females,  while  males  show  an  annual 
decline (-2.4%, p=0.058). In females, there is a significant 
annual rise (8.5%, p=0.008) in AC incidence, which translates 
into an absolute increase from 30 cases/10,000 smokers in 
the year 1994 to 45 cases/10,000 smokers in the year 2000 
(figure 1). 
Table I shows the annual male-to-female (M: F) age-adjusted 
population-standardised incidence rate ratios (RR) for AC, 
SCC  and  total  lung  cancer  cases.  Statistically  significant 
higher RR was observed among ever-smokers. Also, there 
is gradual convergence in RR in the most recent periods, 
suggesting an increasing trend among the females. The ratios 
were relatively low among never-smokers, with very wide 
confidence intervals and unstable estimates, probably due to 
small numbers. 
In table II, almost all the age-standardised incidence rate ratios 
(RR) of AC: SCC are less than ‘one’, especially in smokers of 
Fig 1. Age-standardised annual incidence rates of lung cancer cell-types in the Republic of Ireland from 1994 to 2000 per 
10,000 smokers 
AC M = Lung adenocarcinoma in males; AC F = Lung adenocarcinoma in females; SCC M = Squamous cell carcinoma in males; SCC F = Squamous cell 
carcinoma in females; SCLC M = Small cell lung carcinoma in males; SCLC F = Small cell lung carcinoma in females© The Ulster Medical Society, 2008.
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both sexes, suggesting that SCC incidence 
is still high among the Irish ever-smokers. 
However, the more recent rate ratios of 
AC: SCC is approaching ‘unity’ in female 
ever-smokers, indicating a recent annual 
rise  in AC  incidence  in  females  (table 
I).  Such  ratios  are  also  relatively  high 
in  female  never-smokers,  and  are  not 
statistically significant.
DISCUSSION
Our  study  has  two  important  findings. 
Firstly, our findings may indicate a real 
increase in lung AC incidence in females 
from 1994 to 2000 in Ireland, consistent 
with  other  industrialised  nations.2-4 The 
gradual convergence in ASIR (table I), 
with approaching ‘unity’ ratios between 
AC and SCC (table II), also suggests that 
the  observed  increase  in AC  incidence 
is  less  likely  due  to  the  proportionate 
declining SCC incidence. Secondly, all 
estimates (rates and ratios) indicate that 
females in general are unlikely to have 
a  greater  susceptibility  to  developing 
overall lung cancer, although the ratios 
are changing recently. This is consistent 
with a few of the recent observations6, 7.
The  main  strength  of  our  study  is 
the  analysis  of  lung  cancer  incidence 
data  rather  than  lung  cancer  mortality 
data,  although  the  trend  analysis  was 
apparently  short.  Our  study  did  show 
that  the  total  lung  cancer  incidence 
was significantly increasing in females, 
but  the  fact  that  only  75%  of  lung 
cancer cases were histologically verified 
using  the  Irish  Cancer  Registry  Data 
could have had an impact on the study 
findings. Another  weakness  is  the  lack 
of comprehensive smoking data for the 
individual  patients  analysed.  However, 
the  population  smoking  data  used  in 
our  study  for  the  estimation  of  the 
proportions  of  smokers  and  never-
smokers in Ireland for the baseline year, 
1994 for analysing time-trends was from 
Lee and colleagues’ publication11, and the 
quality of such smoking data has recently 
been reviewed13.
The increase in lung AC incidence is also 
less  likely  due  to  changing  diagnostic 
techniques or better diagnostic facilities, 
because the period studied was relatively 
short. Secondly, evidence suggests that a 
rise in AC incidence could be antecedent 
to diagnostic interventions14. Thirdly, the 
histopathological  criteria  for  diagnosis 
and  classification  have  not  changed 
during  the  study  period.  Fourthly,  the 
WHO’s re-classification of LCC in 1999 
Ta b l e  I. 
M: F Standardized Incidence Rate Ratios (age-adjusted) in ever (former 
and current combined) and never-smokers for total lung cancer cases, Lung 
Adenocarcinoma (AC) and Squamous cell carcinoma (SCC) cases.
   All cases  AC    SCC
Year  RR (95% CI)  RR (95% CI)  RR (95% CI)
Ever-Smokers
1994  1.94 (1.78, 2.12)  1.87 (1.42, 2.43)  2.41 (2.09, 2.78)
1995  1.70 (1.55, 1.86)  1.47 (1.07, 1.93)  2.50 (2.15, 2.90)
1996  1.66 (1.52, 1.82)  1.57 (1.19, 2.01)  1.91 (1.62, 2.23)
1997  1.55 (1.40, 1.70)  1.26 (0.93, 1.66)  2.14 (1.81, 2.49)
1998  1.62 (1.47, 1.77)  1.30 (1.00, 1.65)  2.28 (1.94, 2.67)
1999  1.54 (1.40, 1.68)  1.14 (0.87, 1.47)  2.54 (2.16, 2.96)
2000  1.40 (1.27, 1.54)  1.04 (0.76, 1.38)  1.74 (1.46, 2.08)
Never-Smokers
1994  1.02 (0.51, 1.72)  1.43 (0.44, 3.15)  1.63 (0.51, 3.65)
1995  1.42 (0.74, 2.39)  1.47 (0.33, 4.61)  2.20 (0.41, 5.84)
1996  1.69 (0.86, 2.91)  0.71 (0.12, 3.44)  3.18 (0.99, 9.31)
1997  0.95 (0.42, 1.73)  0.39 (0.01, 3.10)  1.37 (0.33, 4.61)
1998  1.53 (0.83, 2.55)  0.74 (0.08, 2.33)  6.00 (1.56, NC*)
1999  1.14 (0.60, 2.04)  1.39 (0.13, 4.01)  4.00 (1.09, NC*)
2000  1.22 (0.68, 2.10)  1.03 (0.19, 2.74)  2.06 (0.39, 5.48)
* NC: Could not be calculated because of extreme values
Ta b l e  II. 
Age-Standardised Incidence Rate Ratios (RR) of Lung Adenocarcinoma: Squamous 
cell carcinoma (AC: SCC) in ever (former and current combined) and never-
smokers by gender distribution.
  Ever-Smokers    Never-Smokers
  Male  Female  Male  Female
Year  RR (95% CI)  RR (95% CI)  RR (95% CI)  RR (95%CI)
1994  0.3 (0.2, 0.4)  0.4 (0.3, 0.5)  1.0 (0.4, 2.0)  1.2 (0.3, 3.2)
1995  0.3 (0.2, 0.3)  0.5 (0.3, 0.6)  0.8 (0.2, 2.3)  1.3 (0.2, 4.8)
1996  0.4 (0.3, 0.5)  0.5 (0.3, 0.6)  0.4 (0.1, 1.8)  1.9 (0.2, 6.6)
1997  0.3 (0.2, 0.4)  0.5 (0.4, 0.7)  0.3 (0.02, 1.8)  0.9 (0.1, 3.8)
1998  0.4 (0.3, 0.5)  0.7 (0.6, 0.9)  0.5 (0.08, 1.5)  4.4 (0.9, NC*)
1999  0.4 (0.3, 0.5)  0.8 (0.6, 1.0)  0.6 (0.90, 1.6)  1.8 (0.2, 7.2)
2000  0.4 (0.3, 0.5)  0.6 (0.5, 0.7)  1.0 (0.2, 2.3)  2.0 (0.4, 5.5)
* NC: Could not be calculated because of extreme values© The Ulster Medical Society, 2008.
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is  unlikely  to  influence  the AC  trend10,  because  our  data 
suggest an opposite trend in AC incidence between the sexes 
from 1994 to 2000 (figure 1). 
In Ireland, the overall survival rate in lung cancer has not 
improved significantly (from 8.2% in 1994 to 9.0% in 2001)9. 
However,  evidence  suggests  that  females  with  non-small 
cell lung carcinoma can have better survival, following both 
surgery and chemotherapy15,16. This emphasises that females 
may respond differently to tobacco-specific carcinogens for 
certain  cell-types17,18.  Several  molecular  studies  have  also 
suggested  that  sex-differences  in  lung  cancer  biology  do 
exist. Examples include, females having higher DNA adduct 
levels19, an increased CYP1A1 expression19, a decreased DNA 
repair capacity20 and an increased incidence of K-ras gene 
mutations21. A novel oestrogen receptor β was also detected 
in lung tumours22, although both exogenous and endogenous 
oestrogens might be involved in lung AC development23. All 
these indicate that oestrogen signalling could have a biological 
role in lung carcinogenesis.
Unlike the earlier notions of lung AC being more common 
among never-smokers, recent evidence suggests a stronger 
association with smoking, especially in former smokers24. 
Because only 50% of the cigarettes in the late 1960s were 
‘filter-tipped’ in Ireland11, any underlying change in female 
smoking habits is less likely to contribute to the recent lung 
AC incidence increase, similar to a recent study25.  Despite 
small effects, potential environmental risk factor such as air 
quality can have some role26. High residential radon levels 
have also been reported in Ireland27. Lung AC is strongly 
associated  with  asbestos  exposure  levels28,  which  also 
coincides  with  the  increased  mesothelioma  incidence  in 
Ireland29. In summary, rapid urbanization coupled with recent 
lifestyle changes can potentially explain the changing lung AC 
incidence patterns30, 31.
In  March  2004,  the  Republic  of  Ireland  introduced  a 
comprehensive  workplace  smoking  ban32,  with  Northern 
Ireland being the latest to follow suit33. If lung AC is indeed 
strongly  associated  with  smoking  exposure  levels,  then 
a  dramatic  fall  in  lung AC  incidence  over  the  next  few 
years post-ban will certainly confirm the apparent increase 
seen in Ireland. In addition to tobacco-specific carcinogen 
susceptibility  and  gender  variations  in  nicotine  addiction 
levels33, local environmental factors potentially contributing 
to such an apparent increase need to be identified, integrating 
traditional  epidemiological  approaches  with  modern 
molecular techniques32.  To conclude, our study findings do 
not support the hypothesis that females are at a greater risk 
of developing lung cancer, but histologic-specific lung cancer 
susceptibility cannot be ruled out. 
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